Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications

Morton, Rachael L.; Tran, Anh; Vessey, Johan Yusof; Rowbotham, Nick; Winstanley, Julie; Shannon, Kerwin F.; Spillane, Andrew J.; Stretch, Jonathan R.; Thompson, John F.; Saw, Robyn P.M.

doi:10.1245/s10434-017-5842-2

Cited by 10 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were publications on comorbidities in SC patients, HRQoL after treatment and many studies dedicated to different aspects of QoL in different populations of SC patients including studies on behaviour modification, predictors of QoL, predictors of survival, supportive care needs, coping strategies and fear of cancer recurrence…”

Section: Resultsmentioning

confidence: 99%

“…There were publications on comorbidities in SC patients, 113 HRQoL after treatment [118][119][120][121][122][123][124][125][126] and many studies dedicated to different aspects of QoL in different populations of SC patients including studies on behaviour modification, 169,170 predictors of QoL, 171,172 predictors of survival, 173,174 supportive care needs, 175,176 coping strategies 177 and fear of cancer recurrence. 178 Many HRQoL tools have been used in SC patients, with a range of frequency of use.…”

Section: Exclusion Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

Chernyshov

Lallas

Tómas-Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health-related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology-specific, cancer-specific, SC-specific, facial SC-specific, NMSC-specific, basal cell carcinoma-specific and melanoma-specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), Skin Cancer Index (SCI), ShortForm 36 Item Health Survey (SF-36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer-specific EORTC QLQ-C30, especially in late stages of disease, and the melanoma-specific FACT-M and SCspecific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology-specific HRQoL instruments can be used to assess the impact of skin-related problems in SC. The

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Exclusion Criteriamentioning

confidence: 99%

Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

Chernyshov

Lallas

Tómas-Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…SLNB is not a major surgical procedure, but complications, including seroma, wound infection, nerve damage and lymphedema, sometimes occur: a study conducted by Morton et al [ 26 ] suggest that very few patients who underwent SLNB for cutaneous melanoma had objective lymphedema in the long term.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Study of Axillary Lymphatic Drainage in Cutaneous Melanoma Patients: A Cross-Sectional Study

et al. 2023

View full text Add to dashboard Cite

Background: The axilla is a region of fundamental importance for the implications during oncological surgery, and there are many classifications of axillary lymph node subdivision: on the basis of studies on women with breast cancer, we used Clough’s and Li’s classification. However, currently we do not have a gold-standard classification regarding axillary lymphatic drainage in melanoma patients. Purpose: Our aim was to evaluate how these classifications could be adapted to sentinel lymph node evaluation in skin-melanoma patients and to look for a possible correlation between the most recent classifications of axillary lymph node location and Oeslner’s classification, one of the most common anatomical classifications still widespread today. Methods: We analyzed data from 21 patients who underwent sentinel lymph node biopsy between January 2021 and January 2022. Results: Our study demonstrates that, to an extent, there is a possible difference in the use of the various classifications, hinting at possible limits of each. The data we obtained underline how cutaneous melanoma presents extremely heterogenous lymphatic drainage at the level of the axillary cavity. However, the limited data in our possession do not allow us to obtain, at the moment, results that are statistically significant, although we are continuing to enroll patients and collect data. Conclusions: Results of this study support the evidence that the common classifications used for breast cancer do not seem to be exhaustive. Therefore, a specific axillary lymph node classification is necessary in skin melanoma patients.

show abstract

“…The potential benefit of an SLNB must be balanced with the risks of the procedure, which include the risk of permanent lymphedema (\10%). 4 Studies are needed to evaluate the role of SLNB and to identify patients who may benefit from adjuvant therapies in ALM.…”

Section: Treatments and Associated Outcomes Of Acral Lentiginous Melanoma: A Reviewmentioning

confidence: 99%

Treatments and associated outcomes of acral lentiginous melanoma: A review

Lobl

Santos

Clarey

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications

Cited by 10 publications

References 29 publications

Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer

Preliminary Study of Axillary Lymphatic Drainage in Cutaneous Melanoma Patients: A Cross-Sectional Study

Treatments and associated outcomes of acral lentiginous melanoma: A review

Contact Info

Product

Resources

About